GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD

被引：0
|
作者：
Kulkarni, Abhay [1 ]
Das, Sanjib [1 ]
Shelke, Sandeep [1 ]
Pardeshi, Shailesh [1 ]
Bajpai, Malini [1 ]
Potdar, Varada [1 ]
Kadam, Sheetal [1 ]
Bhosale, Vikram [1 ]
Patil, Hansraj [1 ]
Behera, Dayanidhi [1 ]
Udupa, Venkatesha [1 ]
Vinod, K. R. [1 ]
Caracta, Cynthia [2 ]
Iyer, Pravin [1 ]
机构：
[1] Glenmark Pharmaceut Ltd, Glenmark Res Ctr, Mahape, Navi Mumbai 400709, Maharashtra, India
[2] Glenmark Pharmaceut Inc, Clin Sci, 750 Corp Dr, Mahwah, NJ 07430 USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2021年 / 58卷
关键词：
Animal models; COPD; -; mechanism; Anti-; inflammatory;
D O I：
10.1183/13993003.congress-2021.PA2128
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2128
引用
收藏
页数：2
相关论文
共 43 条
  • [1] LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD
    Honnegowda, Srinivasa
    Thomas, Abraham
    Chaudhari, Sachin
    Das, Sanjib
    Shah, Daisy
    Bajpai, Malini
    Sarkar, Indrani
    Kulkarni, Abhay
    Gudi, Girish
    Jadhav, Satyawan
    Khairatkar-Joshi, Neelima
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [2] A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations
    Imura, Chihiro
    Ueyama, Azumi
    Sasaki, Yoshikazu
    Shimizu, Masaya
    Furue, Yoko
    Tai, Nobuyuki
    Tsujii, Kenichiro
    Katayama, Kazufumi
    Okuno, Takayuki
    Shichijo, Michitaka
    Yasui, Kiyoshi
    Yamamoto, Mina
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 93 (03) : 176 - 185
  • [3] Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique "first-in-class" drug for the treatment of COPD & asthma
    Singh, Dave
    Reid, Fred
    Franciosi, Lui
    Walker, Michael
    Page, Clive
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [4] First evidence of efficacy of an orally active RORγt inhibitor in the treatment of patients with moderate to severe plaque psoriasis
    Palmer, S.
    Bryson, C.
    McGeehan, G.
    Lala, D.
    Krueger, J.
    Gregg, R.
    [J]. EXPERIMENTAL DERMATOLOGY, 2016, 25 : 3 - 3
  • [5] A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD
    Vestbo, J.
    Tan, L.
    Atkinson, G.
    Ward, J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (05) : 1039 - 1044
  • [6] First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases
    Borroto, Aldo
    Reyes-Garau, Diana
    Jimenez, M. Angeles
    Carrasco, Esther
    Moreno, Beatriz
    Martinez-Pasamar, Sara
    Cortes, Jose R.
    Perona, Almudena
    Abia, David
    Blanco, Soledad
    Fuentes, Manuel
    Arellano, Irene
    Lobo, Juan
    Heidarieh, Haleh
    Rueda, Javier
    Esteve, Pilar
    Cibrian, Danay
    Martinez-Riano, Ana
    Mendoza, Pilar
    Prieto, Cristina
    Calleja, Enrique
    Oeste, Clara L.
    Orfao, Alberto
    Fresno, Manuel
    Sanchez-Madrid, Francisco
    Alcami, Antonio
    Bovolenta, Paola
    Martin, Pilar
    Villoslada, Pablo
    Morreale, Antonio
    Messeguer, Angel
    Alarcon, Balbino
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (370)
  • [7] VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease
    Fitzpatrick, Leo R.
    Small, Jeff
    O'Connell, Robert
    Talbott, George
    Alton, Gordon
    Zapf, Jim
    [J]. INFLAMMOPHARMACOLOGY, 2020, 28 (02) : 499 - 511
  • [8] VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease
    Leo R. Fitzpatrick
    Jeff Small
    Robert O’Connell
    George Talbott
    Gordon Alton
    Jim Zapf
    [J]. Inflammopharmacology, 2020, 28 : 499 - 511
  • [9] The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD
    Mete, Antonio
    Bowers, Keith
    Bull, Richard J.
    Coope, Helen
    Donald, David K.
    Escott, Katherine J.
    Ford, Rhonan
    Grime, Ken
    Mather, Andrew
    Ray, Nicholas C.
    Russell, Vince
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (23) : 6248 - 6253
  • [10] Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF
    Welk, Vanessa
    Pavlidou, Marina
    Wurzenberger, Claudia
    Hansbauer, Eva-Maria
    Wurzenberger, Cornelia
    Gruner, Stefan
    Peper-Gabriel, Janet
    Jaquin, Thomas
    Konitsiotis, Antonio
    Morgenstern, Josefine
    Prassler, Josef
    Matschiner, Gabriele
    Olwill, Shane
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
12345